Bullish On Bavarian Nordic's Vaccine Portfolio And Revenue Potential In 2025

seekingalpha11-19

Bavarian Nordic holds contracts totaling approximately $340 million for 2025, driven by vaccine demand and global health policies.Its diversified vaccine portfolio targets smallpox, mpox, rabies, tick...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2484928589?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1316007813/image_1316007813.jpg","is_english":true,"pubTime":"2024-11-19 16:34","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2484928589","market":"sh","top_or_hot":-1,"title":"Bullish On Bavarian Nordic's Vaccine Portfolio And Revenue Potential In 2025","media":"seekingalpha","content":"<div>\n<p>Bavarian Nordic holds contracts totaling approximately $340 million for 2025, driven by vaccine demand and global health policies.Its diversified vaccine portfolio targets smallpox, mpox, rabies, tick...</p>\n\n<a href=\"https://seekingalpha.com/article/4738565-bavarian-nordic-stock-bullish-vaccine-portfolio-revenue-potential-2025\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bullish On Bavarian Nordic's Vaccine Portfolio And Revenue Potential In 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBullish On Bavarian Nordic's Vaccine Portfolio And Revenue Potential In 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-19 16:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/article/4738565-bavarian-nordic-stock-bullish-vaccine-portfolio-revenue-potential-2025><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Bavarian Nordic holds contracts totaling approximately $340 million for 2025, driven by vaccine demand and global health policies.Its diversified vaccine portfolio targets smallpox, mpox, rabies, tick...</p>\n\n<a href=\"https://seekingalpha.com/article/4738565-bavarian-nordic-stock-bullish-vaccine-portfolio-revenue-potential-2025\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BVNRY","symbol_name":"Bavarian Nordic A/S","start_time":0,"source_url":"https://seekingalpha.com/article/4738565-bavarian-nordic-stock-bullish-vaccine-portfolio-revenue-potential-2025","article_id":"2484928589","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1316007813/image_1316007813.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484928589","pubTimestamp":1732005286,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Bavarian Nordic holds contracts totaling approximately $340 million for 2025, driven by vaccine demand and global health policies.Its diversified vaccine portfolio targets smallpox, mpox, rabies, tick-borne encephalitis, and investigational areas like chikungunya.BVNKF collaborates with international health organizations, adding both revenue opportunities and dependency risks.Regulatory events in 2025, especially for the chikungunya vaccine, are critical to Bavarian Nordic’s near-term revenue growth.Despite potential regulatory uncertainties, BVNKF trades at a discount relative to peers, with favorable growth prospects and margins, making it a speculative “Buy.”.   Luis Alvarez Bavarian Nordic A/S  is a Danish biotech focusing on vaccines for smallpox, mpox, rabies, tick-borne encephalitis [TBE], and ebola immunizations. The company has secured substantial contracts worth roughly $340 million for 2025. These contracts are related to prophylactic government policies to fight against res","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"BVNRY":"Bavarian Nordic A/S","BVNKF":"Bavarian Nordic A/S"},"translate_title":"看好巴伐利亚北欧公司2025年的疫苗组合和收入潜力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BVNKF":0.9,"BVNRY":0.9},"content_text":"Bavarian Nordic holds contracts totaling approximately $340 million for 2025, driven by vaccine demand and global health policies.Its diversified vaccine portfolio targets smallpox, mpox, rabies, tick-borne encephalitis, and investigational areas like chikungunya.BVNKF collaborates with international health organizations, adding both revenue opportunities and dependency risks.Regulatory events in 2025, especially for the chikungunya vaccine, are critical to Bavarian Nordic’s near-term revenue growth.Despite potential regulatory uncertainties, BVNKF trades at a discount relative to peers, with favorable growth prospects and margins, making it a speculative “Buy.”.   Luis Alvarez Bavarian Nordic A/S (OTCPK:BVNKF) is a Danish biotech focusing on vaccines for smallpox, mpox, rabies, tick-borne encephalitis [TBE], and ebola immunizations. The company has secured substantial contracts worth roughly $340 million for 2025. These contracts are related to prophylactic government policies to fight against resurgent health threats","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"analysis","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2484928589"}